

ALLEGATO B

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n. 1 posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera a) della Legge 240/2010 per il settore concorsuale 06/D3 - Malattie del Sangue, Oncologia e Reumatologia, settore scientifico-disciplinare MED/06 - Oncologia Medica presso il Dipartimento di ONCOLOGIA ED EMATO-ONCOLOGIA (avviso bando pubblicato sulla G.U. 7 del 25/01/2022) Codice concorso 4937

Dario Trapani **CURRICULUM VITAE**

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	TRAPANI	
NOME	DARIO	
DATA DI NASCITA	23/06/1988	
NAZIONALITÀ	ITALIANA	
LINGUA	Italiano (madrelingua), English (<i>OET-certified</i>)	
ORDINE PROFESSIONALE DI APPARTENENZA	Medical Registry No	Full License - SA-10435 (Italy) Medical license (Massachusetts, US) ECFMG-certified physician in US

TITOLI

TITOLO DI STUDIO

(indicare la Laurea conseguita inserendo titolo, Ateneo, data di conseguimento, ecc.)

Laurea in Medicina e Chirurgia, Università degli Studi di Salerno, 25 Ottobre 2013

Specializzazione in Oncologia Medica, Università degli studi di Milano "La Statale", 19 Dicembre 2019

Dottorando in *Drug Innovation*, Università del Piemonte Orientale, 1 Oct 2021 - in corso

CONTRATTI DI RICERCA, ASSEGNI DI RICERCA O EQUIVALENTI ed attività clinico-assistenziale

(per ciascun contratto stipulato, inserire università/ente, data di inizio e fine, ecc.)

World Health Organization, consultant, 1 Marzo 2018 - 1 Settembre 2019

(attività di ricerca in global oncology e cancer policy, con sviluppo di progetti per la programmazione oncologica sanitaria globale e in Paesi low-middle income, la selezione e prioritizzazione di farmaci oncologici ed attività di dialogo ed implementazione di tipo country-missions).

Istituto europeo di Oncologia, fellow di ricerca, 1Agosto 2020 - 30 Giugno 2021

(ricerca ed attività assistenziale per pazienti con tumore mammario e pazienti arruolati in studi di fase 1 - subinvestigator).

Dana Farber Cancer Institute, fellow clinica e di ricerca, 1 Luglio 2021 - in corso
(attività clinico-assistenziale e di ricerca nell'ambito dell'oncologia mammaria)

ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI, O PARTECIPAZIONE AGLI STESSI

- ESMO Leaders Generation Program (alumnus, LGP 2019 class)
- ESMO Faculty - Breast Cancer (member, 2020-2022)
- ESMO Media & Press - committee member, editorial board ESMO Perspectives (2019- in corso)
- ESMO Public Policy committee (membro, 2021-in corso)
- ESMO Magnitude of Clinical Benefit Working Group (membro, 2020-in corso)
- ESMO Precision Medicine Working Group for treatment-individualization (de- escalation) of antineoplastic therapies (2021)
- WHO Cancer Essential Medicines (EML) Working Group (technical expert, 2020-2022)
- WHO SAGE for essential diagnostic in vitro (EDL) (technical expert, 2021-2023)
- WHO Global Breast Cancer Initiative Working Group (clinical expert, 2021-in corso)
- ONCOLLEGE Global Oncology Project - Secretary (2019-in corso)
- ESMO Annual Congress (Paris) 2021, Scientific Committee member - Public Policy
- AIOM Scientific Committee (2021-in Corso)
- Tenwek Hospital Tumour Board (Kenya), member of the clinical panel, breast cancer

ATTIVITÀ DI RELATORE A CONGRESSI E CONVEGNI NAZIONALI E INTERNAZIONALI (inserire titolo congresso/convegno, data, ecc.)

2021 Italian Association of Medical Oncology (AIOM).
ESMO MCBS scale: regulatory and clinical utilizations. Speaker.

2021 European society for Medical Oncology annual meeting (Paris).

Mini-oral session on public policy. Cancer biomarkers. Chair and discussant. ESMO guidelines session: breast cancer. Speaker.

ESMO session on clinical methodology and MCBS. Identifying bias: Top tips when reading a paper. Speaker.

2021 University of Milan. Advanced course in clinical research - GRADE methodology. Lesson: application of GRADE in the development of the Italian and European guidelines for cancer treatment. Teacher.

2021 European School of Oncology (ESO). Conjugated antibodies in breast tumours (E- session 569001: prof Curigliano G). Discussant.

2021 Podcast 'Dr Talk Oncology' (Pensiero Scientifico Editore). Telemedicine and Equity: a double-edged sword reality. Speaker.

2020 MEDSCAPE Oncology - Emerging Data in the Management of Breast Cancer in Light of the COVID-19 Pandemic: Expert Insights from the Clinical Experience in Spain and Italy. Discussant.

2020 European society for Medical Oncology annual meeting, virtual meeting.

- How can we reduce cancer numbers? (ESMO session in collaboration with ASCO), Evidence- based cancer screening interventions.

- The WHO Report on Cancer: What cancer policies are missing in your country? (ESMO and WHO session) - Building cancer services from the ground up: Basic, moderate and advanced health service packages

2020 European society for Medical Oncology OncologyPRO educational webinar: ESMO E- LEARNING: COVID-19 AND CANCER.

2020 European Society for Medical Oncology - ESMO BREAST meeting. Invited discussant of the CANTO cohort study (Di Meglio A, et al).

2020 European Society for Medical Oncology Webinar Series - Breast Cancer in the Era of COVID-19. Speaker: Management of Early Breast Cancer During COVID19 Pandemic

2020 CHINA BREAST CANCER PRECISION MANAGEMENT MULTIDISCIPLINARY

ADVISORY BOARD, China and Italy Hand-in-hand: Breast Cancer Management During 2019-nCoV Outbreak (virtual webinar)

2019 European society for Medical Oncology annual meeting - Barcelona - session "Universal health coverage and cancer: What you and your country need to know" - speaker:

- The methodology and country support for setting cancer priorities for universal health coverage.

2019 AIOM Giovani “News In Oncology”, Perugia - special session “The Global Oncology program: dalla clinica alle policy alle richieste dei pazienti italiani” - speaker:

- Workforce in Global Oncology: il ruolo dell'oncologo medico
- L'accesso all'innovazione in oncologia: quali meccanismi?

2019 ASCO Congress, Chicago - Seminar: (Re)Defining Value in Cancer Care: Priorities for Patients, Providers, and Health Systems. Faculty member and speaker:

- An Update on the Affordability and Effectiveness of Cancer Medicines

2019 Meeting of the Russian national Society of Oncology for children and adolescents, Sochi - speakers:

- Presidential session: An introduction to WHO Global Initiative for Childhood Cancer.

2019 WHO cancer prioritization and costing tool - Consultation of the stakeholders for cancer management and health finance planning, Geneva - speaker:

- Methodology for the selection of cancer intervention and the resource- stratification
- Impact modelling of cancer interventions: Markov multi-state annual transition rates and Kaplan-Meier survival curves, a proposed methodology for conversion.

2019 World Health Organization (Geneva), Visiting Public Health students of the Chicago University.

- Overview of cancer policy: a brief on the ongoing projects in support of the Members States for Cancer Resolution (WHA 70/2017, Cancer Prevention and Control in the Context of an Integrated Approach)
- The relevance of oncology in public health: what are we missing and what can we implement

2019 International Agency for Research on Cancer (IARC). IARC Collaboration for Cancer Classification and Research (IC3R), Inaugural Meeting.

- Attendee, on behalf of WHO for the cancer classification and diagnosis in resource- poor settings

2018 WHO 4th Global Forum on Medical Devices. AMTZ-Kalam Convention Centre, Visakhapatnam (India).

- Panellist of the plenary session I: Medical devices for the management of Noncommunicable diseases - cancer management.

- Speaker - parallel session: WHO Cancer prioritization tool in the context of Universal Health

Coverage: a focus on medical devices.

ESMO congress, Munich (Germany), Cancer Workforce - speaker:

- Session How many patients can one oncologist care for? Health Workforce Planning for Cancer: From Global Commitment to Action

- WHO-ESMO Workforce Survey. How can your country assure enough oncologists for the future?

2018 A Global Initiative in Childhood Cancer: Global Stakeholder Consultation. WHO, Geneva. The National Cancer Planning and the Cancer workforce

2018 ECHO Africa project. Africa Cancer Research and Control Project ECHO Session #4. NCI GlobalHealth US, Bethesda - speaker:

- Cancer workforce methodology tools and strategy: a WHO vision.

2017 ESO- ESMO Preceptorship on Immuno-Oncology 26/05/2017 - 27/05/2017, Amsterdam, The Netherlands. Clinical case: hyperprogression of disease in a triple- negative breast cancer patient receiving pembrolizumab.

2017 16th ESO-ESMO Masterclass in Clinical Oncology. Nauen OT Groß Behnitz (Berlin area), Germany. Clinical case: a case of a woman with multiple locoregional relapses of triple- negative breast cancer in the context of multiple tumours diagnoses - what timing and indication of BRCA testing?

2016 Italian society of medical oncology (AIOM). Young oncologists' national congress (News in oncology), Perugia (Italy) - clinical case:

- Sarcoma and rare tumors: the importance of the second opinion and the referral to centralized care. A case of MPNST, on the way from North Africa to Milan.

CONSEGUIMENTO DI PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA
(inserire premio, data, ente organizzatore, ecc.)

Students merit award, Adisu, Salerno	2013
Chicago Sister Cities Medical Initiative, Lynn Sage Breast Cancer Symposium, LynnSageCancerResearch Foundation travel grant.	2017
European Institute of Oncology merit award for young oncologists	2018
Fondazione IEO-CCM grant for young researchers	2020
Dana-Farber Advanced Fellowship in Breast Oncology	2021

POSSESSO DEL DIPLOMA DI SPECIALIZZAZIONE EUROPEA RICONOSCIUTO DA BOARD INTERNAZIONALI
(relativamente a quei settori concorsuali nei quali è prevista)
(indicare diploma, data di conseguimento, ecc.)

Specializzazione in Oncologia Medica, Università degli studi di Milano “La Statale”, 19 Dicembre 2019

PRODUZIONE SCIENTIFICA

PUBBLICAZIONI SCIENTIFICHE

(per ciascuna pubblicazione indicare: nomi degli autori, titolo completo, casa editrice, data e luogo di pubblicazione, codice ISBN, ISSN, DOI o altro equivalente)

Peer reviewed publications

1. Razis E, Kassapian M, Adriakopolou C, Yehoda MM, Zurn J, Hammad N, Romero Y, Dafni U, Ilbawi MA, Trapani D. Essential Medicines List in National cancer control plans: a secondary analysis from a global study. Lancet Oncol (in press; letter of acceptance and draft attached; publishing on 28th Feb 2022)
2. Duggan C, Trapani D, Ilbawi AM, Fidarova E, Laversanne M, Curigliano G, Bray F, Anderson BO. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncol. 2021 Nov;22(11):1632-1642. doi: 10.1016/S1470-2045(21)00462-9. Epub 2021 Oct 13. PMID: 34653370.

3. Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, Anderson BO, Curigliano G. Global challenges and policy solutions in breast cancer control. *Cancer Treat Rev.* 2022 Jan 19;104:102339. doi: 10.1016/j.ctrv.2022.102339. Epub ahead of print. PMID: 35074727.
4. Trapani D, Murthy SS, Boniol M, Booth C, Simensen VC, Kasumba MK, Giuliani R, Curigliano G, Ilbawi AM. Distribution of the workforce involved in cancer care: a systematic review of the literature. *ESMO Open.* 2021 Nov 8;6(6):100292. doi: 10.1016/j.esmoop.2021.100292. PMID: 34763251.
5. Trapani D, Curigliano G. Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021. 2021. *Breast.* DOI: 10.1016/j.breast.2021.12.012
6. Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. *Lancet Oncol.* 2021 Oct;22(10):1367-1377. doi: 10.1016/S1470-2045(21)00463-0. Epub 2021 Sep 21. PMID: 34560006; PMCID: PMC8476341.
7. Trapani D, Curigliano G. COVID-19 vaccines in patients with cancer. *Lancet Oncol.* 2021 Jun;22(6):738-739. doi: 10.1016/S1470-2045(21)00250-3. PMID: 34087120; PMCID: PMC8169039.
8. Trillo Aliaga P, Trapani D, Sandoval JL, Crimini E, Antonarelli G, Vivanet G, Morganti S, Corti C, Tarantino P, Friedlaender A, Belli C, Minchella I, Locatelli M, Esposito A, Criscitiello C, Curigliano G. Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. *Cancers (Basel).* 2021 Nov 20;13(22):5829. doi: 10.3390/cancers13225829. PMID: 34830983; PMCID: PMC8616209.
9. Khan SZ, Arecco L, Villarreal-Garza C, Sirohi B, Ponde NF, Habeeb B, Brandão M, Azim HA Jr, Chowdhury AR, Bozovic-Spasojevic I, Kovalenko I, Odhiambo A, Seid FU, Mutombo AB, Petracci F, Vidra R, Altuna SC, Petrova M, Kourie HR, Ozturk MA, Razeti MG, Lengyel CG, Talibova N, Mariamidze E, Sacardo KP, Duma N, Gyawali B, Trapani D, Tagliamento M, Lambertini M. Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. *JCO Glob Oncol.* 2022 Jan;8:e2100153. doi: 10.1200/GO.21.00153. PMID: 35025688; PMCID: PMC8769103.
10. Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivanet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G. Evolution of low HER2 expression between early and advanced-stage breast cancer. *Eur J Cancer.* 2022 Jan 12;163:35-43. doi: 10.1016/j.ejca.2021.12.022. Epub ahead of print. PMID: 35032815.
11. van der Hage J, Sandrucci S, Audisio R, Wyld L, Søreide K; ESSO core curriculum contributors, Amaral T, Audisio R, Bahadoer V, Beets G, Benstead K, Berge Nilsen E, Bol K, Brandl A, Braun J, Cufer

T, Dopazo C, Edhemovic I, Eriksen JG, Fiore M, van Ginhoven T, Gonzalez-Moreno S, van der Hage J, Hutteman M, Masannat Y, Onesti EC, Rau B, De Reijke T, Rubio I, Ruurda J, Sandrucci S, Soreide K, Stattner S, Trapani D, D'Ugo D, Vriens M, Wyld L, Zahl Eriksson AG. The ESSO core curriculum committee update on surgical oncology. *Eur J Surg Oncol*. 2021 Nov;47(11):e1-e30. doi: 10.1016/j.ejso.2021.10.003. Epub 2021 Oct 13. PMID: 34657781.

12. Nicolò E, Trapani D, Berton Giachetti PPM, Zagami P, Curigliano G. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. *Cancer Treat Rev*. 2021 Nov;100:102281. doi: 10.1016/j.ctrv.2021.102281. Epub 2021 Aug 18. PMID: 34500366.

13. Trapani D, Yves Douillard J, Winer EP, Burstein H, Anne Carey L, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G & Ilbawi AM. The global landscape of treatment standards for breast cancer. *J Natl Cancer Inst*. 2021 Jan 27:djab011. doi: 10.1093/jnci/djab011. Epub ahead of print. PMID: 33502535.

14. Trapani D, C.G.Lengyelc, B.S.Habeeb, S.C.Altuna, A.Petrillo, El Bairi, S.Hussain, S.A.Mazheri, E.M.Elfaham, G.Curigliano, S.Z.Khan. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. June 2021. <https://doi.org/10.1016/j.jcpo.2021.100285> J Cancer Policy.

15. Trapani D, Curigliano G. The global landscape of drug development of trastuzumab biosimilars. *J Cancer Policy* Volume 28, June 2021, 100273.

16. Nicolò E, Trapani D, Berton Giachetti PPM, Zagami P, Curigliano G. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. *Cancer Treat Rev*. 2021 Aug 18;100:102281. doi: 10.1016/j.ctrv.2021.102281. Epub ahead of print. PMID: 34500366.

17. Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO- MCBS) scoring. *ESMO Open*. 2021 Apr 19;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub ahead of print. PMID: 33887690; PMCID: PMC8086024.

18. Trapani D, Giugliano F, Uliano J, Zia VAA, Marra A, Viale G, Ferraro E, Esposito A, Criscitiello C, D'amico P, Curigliano G. Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. *Breast Cancer Res Treat*. 2021 Jun;187(2):323-337. doi: 10.1007/s10549-021-06259-8. Epub 2021 May 27. PMID: 34043122.

19. Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, Criscitiello C, Tarantino P, Curigliano G. Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. *Cancer Treat Rev.* 2021 Jun;97:102205. doi: 10.1016/j.ctrv.2021.102205. Epub 2021 Apr 9. PMID: 33878560.
20. Tarantino P, Trapani D, Curigliano G. Mastering the Use of Novel Anti-HER2 Treatment Options. *JCO Oncol Pract.* 2021 Jun 2:OP2100216. doi: 10.1200/OP.21.00216. Epub ahead of print. PMID: 34077256.
21. Yekedüz E, Trapani D, Xu W, de Vries EG, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Ürün Y. Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors. *Int J Cancer.* 2021 Jun 14. doi: 10.1002/ijc.33708. Epub ahead of print. PMID: 34124786.
22. Filetti M, Trapani D, Cortellini A, Cofini V, Necozone S, James Pinato D, Porzio G, Marchetti P, Giusti R. Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. *Support Care Cancer.* 2021 Jun 26. doi: 10.1007/s00520-021-06383-7. Epub ahead of print. PMID: 34176017.
23. Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). *Clin Cancer Res.* 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. PMID: 33785482.
24. Safi M, Al-Azab M, Jin C, Trapani D, Baldi S, Adlat S, Wang A, Ahmad B, Al-Madani H, Shan X, Liu J. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study. *Front Immunol.* 2021 Nov 16;12:609728. doi: 10.3389/fimmu.2021.609728. PMID: 34887846; PMCID: PMC8650702.
25. Lengyel CG, Hussain S, Seeber A, Jamil Nidhamalddin S, Trapani D, Habeeb BS, Elfaham E, Mazher SA, Seid F, Khan SZ, El Bairi K, Odhiambo A, Altuna SC, Petrillo A. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target? *Life (Basel).* 2022 Jan 7;12(1):81. doi: 10.3390/life12010081. PMID: 35054474; PMCID: PMC8778800.
26. Giugliano F, Crimini E, Tarantino P, Zagami P, Uliano J, Corti C, Trapani D, Curigliano G. First line treatment of BRAF mutated advanced melanoma: Does one size fit all? *Cancer treatment reviews,* Sept 2021.

27. Safi M, Al-Nusaif M, Trapani D, Mashrah MA, Kanesvaran R, Alzandani A, Al-Azab M, Mazher SA, Al-Danakh A, Liu J. Brain and heart-specific death in cancer patients: Population-based study. *Cancer Med.* 2021 Sep;10(17):5739-5747. doi: 10.1002/cam4.4069. Epub 2021 Aug 10. PMID: 34374226; PMCID: PMC8419745.
28. Safi M, Trapani D, Alradhi M, Shan X, Jiwei L. Letter to the editor: No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma. *Pathol. Oncol. Res.* 2021
29. Elit L, Haruyama R, Gatti A, Howard SC, Lam CG, Fidarova E, Angioli R, Cao X, Trapani D, Ilbawi A. Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports. *ESMO Open.* 2020 Nov;5(6):e000878. doi: 10.1136/esmoopen-2020-000878. PMID: 33310778; PMCID: PMC7783605.
30. Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple- negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. *NPJ Breast Cancer.* 2020 Oct 16;6:54. doi: 10.1038/s41523-020-00197-2. PMID: 33088912; PMCID: PMC7568552.
31. Tarantino P, Mazzeella L, Marra A, Trapani D, Curigliano G. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. *Cancer Treat Rev.* 2021 Feb 20;94:102169. doi: 10.1016/j.ctrv.2021.102169. Epub ahead of print. PMID: 33652262.
32. Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol.* 2021 Jan 19:103223. doi: 10.1016/j.critrevonc.2021.103223. Epub ahead of print. PMID: 33482345.
33. Ghidini M, Fusco N, Salati M, Khakoo S, Tomasello G, Petrelli F, Trapani D, Petrillo A. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. *Curr Drug Targets.* 2021 Feb 4. doi: 10.2174/1389450122666210204204415. Epub ahead of print. PMID: 33563194.
34. Indini A, Nigro O, Lengyel CG, Ghidini M, Petrillo A, Lopez S, Raspagliesi F, Trapani D, Khakoo S, Bogani G. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. *Cancers (Basel).* 2021 Apr 1;13(7):1663. doi: 10.3390/cancers13071663. PMID: 33916221; PMCID: PMC8037571.
35. Ghidini M, Petrillo A, Botticelli A, Trapani D, Parisi A, La Salvia A, Sajjadi E, Piciotti R, Fusco N, Khakoo S. How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. *J Clin Med.* 2021 Apr 1;10(7):1412. doi: 10.3390/jcm10071412. PMID: 33915839; PMCID: PMC8037391.

36. Lengyel CG, Hussain S, Trapani D, El Bairi K, Altuna SC, Seeber A, Odhiambo A, Habeeb BS, Seid F. The Emerging Role of Liquid Biopsy in Gastric Cancer. *J Clin Med*. 2021 May 13;10(10):2108. doi: 10.3390/jcm10102108. PMID: 34068319; PMCID: PMC8153353.
37. Petrillo A, Salati M, Trapani D, Ghidini M. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients. *Curr Drug Targets*. 2020 Nov 3. doi: 10.2174/1389450121999201103194248. Epub ahead of print. PMID: 33155906.
38. Lengyel CG, Habeeb B, Khan SZ, El Bairi K, Altuna SC, Hussain S, Mazher SA, Trapani D & Petrillo A. Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. *Gastrointestinal Disorders*. 2021; 3(1):1-22. <https://doi.org/10.3390/gidisord3010001>
39. Trapani, D., Giugliano, F., El Bairi, K., Uliano, J., Belli, C., & Curigliano, G. (2021). Caveats, Nuances and Benefits of the Clinical Use of granulocyte Colony-Stimulating Factors in Cancer Patients with Coronavirus Disease 2019. *Cancer Cells and Therapy*, 1(1), 1-7. Retrieved from <https://www.medcliph.com/index.php/cct/article/view/5>
40. El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S. Repurposing anticancer drugs for the management of COVID-19. *Eur J Cancer*. 2020 Dec;141:40-61. doi: 10.1016/j.ejca.2020.09.014. Epub 2020 Sep 22. PMID: 33125946; PMCID: PMC7508523.
41. Petrillo A, Salati M, Trapani D, Ghidini M. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients. *Curr Drug Targets*. 2020 Nov 3. doi: 10.2174/1389450121999201103194248. Epub ahead of print. PMID: 33155906.
42. Lemine Sow M, El Yacoubi H, Moukafih B, Balde S, Akimana G, Najem S, El Khoyaali S, Abahssain H, Chaibi A, Zeb Khan S, Trapani D, Benzekri A, Ghaouti M, Gamra L, Mestari A, Kettani F, Rahali Y, Mrabti H, Elghissassi I, Errihani H. Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer. *Tumori*. 2020 Oct 20:300891620964571. doi: 10.1177/0300891620964571. Epub ahead of print. PMID: 33079008.
43. Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietrolungo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. *J Immunother Cancer*. 2020 Oct;8(2):e001154. doi: 10.1136/jitc-2020-001154. PMID: 33060148; PMCID: PMC7565202.

44. Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, Burger EA, Martin D, Nguyen DTN, Bénard É, Sy S, Regan C, Drolet M, Gingras G, Laprise JF, Torode J, Smith MA, Fidarova E, Trapani D, Bray F, Ilbawi A, Broutet N, Hutubessy R. Mortality Impact of Achieving WHO Cervical Cancer Elimination Targets: A Comparative Modelling Analysis in 78 Low-Income and Lower-Middle-Income Countries. *Lancet*. 2020 Feb 22;395(10224):591- 603. doi: 10.1016/S0140-6736(20)30157
45. Trapani D, Zagami P, Nicolò E, Pravettoni G, Curigliano G. Management of Cardiac Toxicity Induced by Chemotherapy. *J Clin Med*. 2020 Sep 7;9(9):E2885. doi: 10.3390/jcm9092885. PMID: 32906611.
46. Corti C, Crimini E, Criscitiello C, Trapani D, Curigliano G. Adjuvant treatment of early male breast cancer. *Curr Opin Oncol*. 2020 Aug 26. doi: 10.1097/CCO.0000000000000678. Epub ahead of print. PMID: 32852309.
47. Trapani D, Curigliano G. How to treat lobular cancer in the adjuvant setting? *Curr Opin Oncol*. 2020 Aug 19. doi: 10.1097/CCO.0000000000000674. Epub ahead of print. PMID: 32826487.
48. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol*. 2020 Oct;31(10):1320- 1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31. PMID: 32745693 (panel member)
49. Trapani D, Curigliano G, Alexandru E, Sternberg CN. The global landscape of drug development for kidney cancer. *Cancer Treat Rev*. 2020 Sep;89:102061. doi: 10.1016/j.ctrv.2020.102061. Epub 2020 Jun 23. PMID: 32738737.
50. Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G. Pharmacological management of male breast cancer. *Expert Opin Pharmacother*. 2020 Aug;21(12):1493-1504. doi: 10.1080/14656566.2020.1763305. Epub 2020 Jun 4. PMID: 32496137.
51. de Azambuja E*, Trapani D* (first author), Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnani M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. *ESMO Open*. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793. PMID: 32439716; PMCID: PMC7295852. *co-first
52. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. *Eur J Cancer*. 2020 Jun;132:199-206. doi: 10.1016/j.ejca.2020.04.017. Epub 2020 Apr 29. PMID: 32380430; PMCID: PMC7188643.

53. Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*. 2020 May 5;25(9):803-9. doi: 10.1634/theoncologist.2020-0014. Epub ahead of print. PMID: 32369650; PMCID: PMC7485362.

54. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, André F, Curigliano G. HER2-Low Breast Cancer: Pathological and Clinical Landscape. *J Clin Oncol*. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. PMID: 32330069.

55. El Bairi K, Jabi R, Trapani D, Boutallaka H, Ouled Amar Bencheikh B, Bouziane M, Amrani M, Afqir S, Maleb A. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. *Expert Rev Clin Pharmacol*. 2020 Apr;13(4):403-421. doi: 10.1080/17512433.2020.1758063. Epub 2020 May 24. PMID: 32308061.

56. Tarantino P, Trapani D, Curigliano G. Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic. *Eur J Cancer*. 2020 Jun;132:8-10. doi: 10.1016/j.ejca.2020.03.023. Epub 2020 Apr 6. PMID: 32305011; PMCID: PMC7136890.

57. Mazzearella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? *J Immunother Cancer*. 2020 Mar;8(1):e000475. doi: 10.1136/jitc-2019-000475. PMID: 32238471; PMCID: PMC7174064.

58. Passaro A, Mackenzie G, Lambertini M, Morgan G, Zimmermann S, Garrido P, Curigliano G, Trapani D. European Society for Medical Oncology (ESMO) 2018 Congress Twitter Analysis: From Ethics to Results Through the Understanding of Communication and Interaction Flows. *ESMO Open*. 2020 Feb;5(1):e000598. doi: 10.1136/esmoopen-2019-000598

59. Trapani D, Curigliano G. How can biosimilars change the trajectory of breast cancer therapy? (Editorial) *Expert Rev Anticancer Ther*. 2020 May;20(5):325-328. doi: 10.1080/14737140.2020.1757438. Epub 2020 Apr 28. PMID: 32298188.

60. Curigliano G, Bagnardi V, Ghioni M, Louahed J, Brichard V, Lehmann FF, Marra A, Trapani D, Criscitiello C, Viale G. Expression of tumor-associated antigens in breast cancer subtypes. *Breast* 2019

61. Trapani D, Curigliano G, Eniu A. Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. *Breast Care (Basel)*. 2019 Dec;14(6):373-381. doi: 10.1159/000502637. Epub 2019 Sep 24. PMID: 31933583; PMCID: PMC6940432.

62. Lengyel CG, Altuna SC, Habeeb BS, Trapani D, Khan SZ. The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas. *Curr Drug Targets* 2019
63. Ferraro E, Trapani D, Marrucci E, Curigliano G. Evaluating triptorelin as a treatment option for breast cancer. *Expert Opin Pharmacother* 2019
64. Romero Y*, Trapani D* (first autor), Johnson S, Tittenbrun Z, Given L, Hohman K, Stevens L, Torode JS, Boniol M, Ilbawi AM. National cancer control plans: a global analysis. *Lancet Oncol.* 2018.
65. Mazzearella, Duso BA, Trapani D, Belli C, D'amico P, Ferraro E, Viale G, Curigliano G. The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review. *Eur J Cancer.* 2019
66. Eniu A, Cherny NI, Bertram M, Thongprasert S, Douillard JY, Bricalli G, Vyas M, Trapani D. Cancer medicines in Asia and Asia-Pacific: What is available and is it effective enough? *ESMO Open* 2019
67. Trapani D, Rajasekar AKA, Mathew A. More options for adjuvant treatment of HER2- positive breast cancer: How to choose wisely? *Int J Cancer.* 2019
68. Willenbacher E, Khan SZ, Mujica SCA, Trapani D, Hussain S, Wolf D, Willenbacher W, Spizzo G, Seeber A. Curcumin: New Insights into an Ancient Ingredient against Cancer. *Int J Mol Sci.* 2019
69. Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. *Crit Rev Oncol Hematol.* 2019
70. Belli C, Zuin M, Mazzearella C, Trapani D, D'amico P, Guerini- Rocco E, Achutti Duso B, Curigliano G. Liver toxicity in the era of immune checkpoint inhibitors: a practical approach. *Critical Reviews in Oncology Hematology* , 2018.
71. Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, Belli C, Mazzearella L, Locatelli M, Minchella I, Curigliano G. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother.* 2018.
72. Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, Curigliano G. Targeting the microenvironment in solid tumors. *Cancer Treat Rev.* 2018.

73. Giulia Viale, Dario Trapani, and Giuseppe Curigliano, "Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy," *BioMed Research International*, vol. 2017, Article ID 4719194, 7 pages, 2017.

74. Trapani D, Criscitiello C, Esposito A, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Entinostat for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2017.

75. Esposito A, Criscitiello C, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. *Curr Oncol Rep*. 2017 Jan;19(1):1.

76. Migali C, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Therapeutic advances in medical oncology*, July 2015.

77. Trapani D, Curigliano G. Genomic analysis of circulating tumor DNA to predict endocrine resistance and clonal evolution in patients with prostate cancer: Clinical perspectives and research opportunities. *Transl Cancer Res* 2016;5(Suppl 4):S800-S802.

78. Criscitiello C, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev*. 2016 Oct 6;50:205-207.

79. Trapani D, Conforti F, De Pas M. EGFR inhibition in a pretreated sacral chordoma: a role for erlotinib? Case report and a brief review of literature. *Trasl med* 2015.

80. Trapani D, Bonzi M. Antibiotic treatment strategies for community-acquired pneumonia in adults. The cutting edge: research update. *Internal and Emergency Medicine* (October 2015), 10(7): 861- 863.

Book chapters

1. World Health Organization. WHO Report on Cancer: setting priorities, investing wisely and providing care for all. 2020. ISBN. 9789240001299. Available at: <https://apps.who.int/iris/handle/10665/330745>.

2. World Health Organization. WHO framework for strengthening and scaling-up services for the management of invasive cervical cancer. 2021. ISBN 978-92-4-000323. Available at: <https://www.who.int/publications/i/item/9789240003231>

3. World Health Organization. Guide for establishing a pathology laboratory in the context of cancer control. **ISBN:** 9789241516938. Available at: <https://apps.who.int/iris/handle/10665/330664>
4. Principles of extrapolation in Biosimilars Oncology. Minerva Medica. Dec2019
5. El Bairi K, Al Jarroudi O, Carpenito L, Trapani D, Afqir A. The advent of circulating tumor DNA in the management of ovarian cancer - DOI: 10.1007/978-981-16-1873-4_5 Springer ed, Oct 2021.
6. Sternberg CN, Trapani D, Eniu A. ASCO SEP. Global Oncology Perspective: Genitourinary Cancers (7th ed)
7. Sternberg CN, Trapani D, Eniu A. ASCO SEP. Global Oncology Perspective: Genitourinary Cancers (7th ed, May 2021 update)
8. Trapani D, Curigliano G. Tailoring chemotherapy and biological treatment in young patients with EBC. Breast Cancer in Young Women. Tailoring chemotherapy and biological treatment in young patients with EBC. Breast Cancer in Young Women, 2020. DOI: 10.1007/978-3-030-24762-1_10
9. Trapani D, Eniu A. Inflammatory Breast cancer. Breast Cancer Essentials, Perspectives for Surgeons. Springer (publishing) - 2019 DOI: 10.1007/978-3-030-73147-2_55
10. Trapani D, Curigliano G. Systemic Impact of Breast Reconstruction in Oncoplastic and Reconstructive Breast Surgery, 2nd edition. eBook ISBN 978-3-319-62927-8 Springer International Publishing, 2019.
11. Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing: A Big Chapter in the Tale. Springer. Chapters: Cost-Effectiveness and Limitations of Next- Generation Sequencing in Colorectal Cancer. A molecularly- driven treatment decision in metastatic colorectal cancer treatments. Current clinical practice and perspectives. Management of colorectal cancer in the era of precision medicine. Springer medicine. ISBN 978-3-030-53821-7 (El Bairi K editor).
13. Vv.Aa. Oncologia medica (medical oncology). Test di accesso alle scuole di specializzazione in medicina (Test preparation book for medical residency test). EdiErmes (2014 & reprints) - text in Italian language

Non peer reviewed literature

ESMO perspectives (Dec 2021) - Fair pricing in an unfair world — where is the value?

ESMO perspectives (Juy 2021) - One step back to move forward in oncology workforce

ESMO perspectives (February 2021) - Are we ready to accept uncertainty in the name of cancer care sustainability?

DECIDE hub (February 2021) - Post COVID-19: more than oncology. Better oncology!

ESMO perspectives (June 2021) - Making assumptions about COVID-19 and cancer: a way to harm all

DECIDE hub (June 2021) - Waiving Patents for COVID19 Vaccines: Solution or Threat for pandemic control? (with Sullivan R & Curigliano G.

ESMO Daily Reporter, Annual meeting 2021 - The tipping point of cancer biomarker quality.

ASCO Daily (Nov 2021). Duration of Endocrine Therapy in Breast Cancer: How Much of a Good Thing Is Too Much? (Dr Burstein H).

ESMO Perspectives (December 2021) - Fair pricing in an unfair world: where is the value?

Info.BREAST editorials (in Italian, years 2020-2021)

- HER2CLIMB: un efficace paradigma di studio del tumore mammario HER2-positivo nelle popolazioni sotto- rappresentate negli studi clinici
- Un cavallo di Troia innovativo nel destino del tumore mammario HER2- positivo
- Quale spazio terapeutico per il doppio blocco recettoriale nella terapia adiuvante del tumore mammario HER2-positivo?
- Integratori durante la chemioterapia per il tumore mammario: tu quoque, Brute
- Le fluoropirimidine fanno ancora una volta la differenza nel tumore mammario precoce
- Nuove evidenze sulla via della de- escalation nel trattamento adiuvante del tumore mammario HER2- positivo in stadio I.
- Nuove pillole di farmacologia oncologica: il paclitaxel per os nel tumore mammario omettere o non omettere la chirurgia mammaria nei pazienti con risposta clinica e radiologica completa, dopo terapia neoadiuvante?
- Nuove evidenze e nuovi dubbi per l'immunoterapia nel tumore mammario triplo-negativo in stadio precoce: cui prodest?
- A cosa bisogna porre maggiormente attenzione nella gestione clinica delle donne con tumore mammario, oltre all'andamento della malattia oncologica?
- Mantenersi attive dopo il trattamento del tumore mammario? Le donne francesi ce la mettono tutta!
- Le basi biologiche del tumore mammario HER2-low: una nuova entità biologica?
- Inibitori di PARP nelle donne con tumore mammario avanzato e portatrici di mutazione germinale dei geni BRCA 1 o 2. Quali novità nei trattamenti?
- Tumore triplo-negativo della mammella e nuovi segnali di beneficio dell'immunoterapia: la chiave è nella selezione dei pazienti
- Terapie endocrine a confronto per il trattamento del tumore mammario avanzato, positivo al recettore degli estrogeni e negativo ad HER2: il tête-à-tête dello studio PARSIFAL
- Una nuova strategia farmacologica per le pazienti con tumore mammario HER2- positivo e metastasi encefaliche in progressione
- La sessualità dopo la diagnosi di tumore mammario. Come tenerne conto nella scelta della terapia ormonale adiuvante?
- Un anno di neratinib: dove si posiziona nel trattamento del tumore mammario HER2 positivo nel 2020?
- Tumore della mammella: cosa cambia per le pazienti dopo la diagnosi oncologica?
- L'autosomministrazione di farmaci biologici a casa: ancora un'utopia in oncologia? Un recente studio con il trastuzumab potrebbe cambiare il paradigma di healthcare delivery
- Trastuzumab in monoterapia come trattamento adiuvante per il tumore mammario HER2-positivo: pazzia idea?
- Nessun progresso senza conflitto: la storia dei farmaci CDK4/6 inibitori nel trattamento adiuvante del tumore mammario è appena cominciata.
- Lo sviluppo delle piccole molecole per il trattamento del tumore mammario HER2 è in continua evoluzione: quali novità sul neratinib?
- T-DM1 per il trattamento del tumore mammario HER2-positivo con metastasi encefaliche? Nuove evidenze rimettono la molecola in gioco.
- Un nuovo approccio farmacologico per il tumore mammario triplo- negativo: una rivoluzione terapeutica?
- Tinture permanenti per capelli: quale rischio per il tumore della mammella? Uno studio recentissimo sembra mettere in chiaro la questione
- Le ultime news sul neratinib dal San Antonio Breast Cancer Symposium 2020: come cambia la pratica clinica?
- Che ne facciamo degli inibitori delle chinasi ciclina- dipendente 4 e 6 nel setting adiuvante del tumore mammario, ora? Nuovi dati, a complicare i fatti.
- A che punto siamo con le strategie di prevenzione e controllo del tumore

mammario nei piani nazionali di oncologia?

- Screening mammografico per la diagnosi precoce del tumore mammario: quanto serve e perché è imperativo ripartire!
- Nella scelta della terapia adiuvante per le pazienti con tumore mammario endocrino- responsivo, vince l'approccio costruito intorno al paziente.
- Strategie di mantenimento con un regime terapeutico de- intensificato nella prima linea metastatica per le pazienti con tumore mammario. Le nuove evidenze, dall' Oriente La partecipazione dei pazienti agli studi clinici oncologici è una questione di Volere o Potere?
- Comorbidità psichiatriche nelle donne con una diagnosi di tumore della mammella: come cambia la gestione oncologica?
- Neratinib: nuovi dati consolidano ulteriormente il ruolo nella malattia HER2-positiva.
- Nuovi dati sulle signature genomiche nelle donne premenopausali con tumore mammario operato: è ancora una questione di interpretazione?
- Antracicline o Sali di Platino nel trattamento neoadiuvante del carcinoma mammario triplo-negativo?
- Vaccino per il COVID19 nelle donne con tumore mammario: avanti, in sicurezza!
- L'Organizzazione Mondiale della Sanità lancia la Global Breast Cancer Initiative – una nuova speranza per tutte le donne del mondo!
- Novità in tema di terapia endocrina adiuvante negli uomini con tumore della mammella: inibitori delle aromatasi sì o no?
- Screening del tumore al seno nelle persone transgender: chi, quando e come?
- Tumore della mammella ER-low-positive: una nuova entità oppure un revival?
- Un nuovo "tentativo" di de-escalation della terapia adiuvante nelle pazienti con tumore mammario HER2-positivo: questa volta, senza chemioterapia!
- Cardiotossicità e nuove immunoterapie adiuvanti per il tumore mammario: quanto possiamo stare tranquilli?
- La saga della capecitabina post-neoadiuvante nel tumore triplo-negativo: secondo episodio - il testa a testa col platino.
- Un prezioso focus sul tumore lobulare della mammella: fresche evidenze dallo studio GELATO.
- Medicina integrativa, complementare e alternativa per le pazienti con tumore della mammella: facciamo chiarezza!
- Il trattamento adiuvante esteso con neratinib nel tumore mammario HER2-positivo: quanto è importante completare un anno di trattamento?
- Un farmaco target per il trattamento adiuvante del tumore mammario in pazienti con mutazione germinale di BRCA: è già sul podio della vittoria?
- Attenti alle tempistiche nel definire il priority-setting: gli screening oncologici non vanno messi in secondo piano per sempre!
- Un nuovo incentivo alla de-escalation del trattamento adiuvante per le pazienti con tumore mammario HER2-positivo: back from #ESMO21
- Tumori lobulari della mammella: chemioterapia adiuvante possibile oppure chemioterapia adiuvante giammai?
- Carboplatino neoadiuvante nel tumore triplo-negativo della mammella: dubitare è lecito, non cambiare la pratica clinica è buon senso.
- Eventi coronarici acuti nei pazienti con tumore mammario metastatico: è sempre opportuno un approccio conservativo?
- Nuove evidenze su COVID19 e Cancro: cosa abbiamo appreso ulteriormente?
- A digiuno o dopo i pasti? Farmaci oncologici per il tumore mammario ed interazioni con la dieta.
- Neratinib: nuovi insights per l'uso adiuvante nel setting ad alto rischio
- La prevenzione del tumore mammario nelle donne con comorbidità psichiatrica: attenzione ai farmaci neurolettici
- EMERALD: è tempo di riconsiderare il disegno degli studi di fase 3?
- Programmi di prevenzione e cura del cancro mammario: l'investment case dell'OMS.
- Prendersi cura delle donne con tumore mammario in stadio 1-3: una questione di "cuore".
- ELEANOR, dicci: come performa il neratinib in real-life?

- COVID19 e tumore mammario: che succederà?
- Il profiling molecolare nel tumore mammario metastatico: l'idea del SAFIR02-BREAST.
- Antracicline nella terapia adiuvante del tumore mammario HER2-negativo: le intoccabili!
- Novità in materia di resistenza ai farmaci anti-HER2 nel tumore mammario: il caso MAPK.

BIOGRAPHICAL SKETCH

Dario Trapani, MD, is a practicing medical oncologist trained in Milan, presently enrolled in a clinical and research fellowship at Dana Farber Cancer Institute, Boston. Dario has a research interest for breast cancer, new drugs, health policy, global oncology and methodology of clinical trials. Dr Trapani has been trained in medical oncology at the University of Milan and at the European Institute of Oncology (Milan), mentored by prof Curigliano. He gained expertise in the conceptualization, analysis, development and deployment of early-phase clinical trials, with a disease-oriented interest in breast cancer. As a fellow at IEO, Dario has also worked as a sub-investigator for several phase 1 clinical trials. He has supported the development of innovative therapies with new small molecules and immune-checkpoint inhibitors, intra-tumor injective compounds, as single agents and in combination, in all the disease settings. He has contributed to the patient evaluation and care as a clinician, including in the early recognition, diagnosis and management of emerging or uncommon adverse effects. As a fellow at Dana Farber, Dario is working on clinical trial concepts aiming at preventing and overcoming endocrine resistance of advanced breast cancer, and enable better outcomes through strategies of improvement of the patient adherence to therapies in the early setting. As a chief resident and then as a fellow, Dario has worked under the principles of inclusive team working aiming at canalizing the group efforts and catalyze scientific initiatives, with an open attitude toward empowering value of diversity. Dr Trapani has then enrolled in a consultancy position for cancer policy at the World Health Organization headquarter in Geneva, for 2 years, where he has contributed to the tracks of prioritization and selection of cancer interventions – including for shaping benefits package of Universal Healthcare and Essential Medicines. The major focus at WHO was the development of evidence-based methodologies to develop and implement impactful national cancer control plans, based on a resource-stratified approach. Framing the continuum of this experience, Dr Trapani is a member of the PhD-candidates working group of AIFA, helping in the evaluation of clinical trial concepts and value of new cancer medicines for the clinical benefit-harm assessment. Presently, he sits in two high-level WHO committees, in the expert roster for Global Cancer Control, in one WHO Strategic Advisory Board of Experts (SAGE) and 2 technical Working Groups, including the Global Breast Cancer Initiative. As a clinician, Dario is involved in the clinical research for breast cancer. He has also joined recently the Harvard Medical School PORTAL (policy and regulations) group, working on the evaluation of breast cancer medicines. Dario has worked on a number of scientific publications and technical reports, and supported several meetings, including in speaker position. He is member of ESMO, ASCO, AIOM, ESO and presently serves ESMO in multiple committees. Dr Trapani has interest in the evaluation and implementation of clinically relevant and patient-centered endpoints in the clinical research for (breast) cancer care, including for the treatment customization and pertinently to the global cancer control, including and not limited in low- and middle-income countries, and to accelerate progress toward regulatory purposes and deliver better patient care.

Authorizing the processing of personal data as defined by D. Decree Law 196/2003.

Data

21 Febbraio, 2022

Luogo

Boston (MA), US